Protagonist Therapeutics Inc. Overview
Pro stress-test →Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on peptide-based therapies targeting validated pathways in immunology and inflammation, hematology and metabolic diseases. The company has an advanced and diversified clinical pipeline anchored by two potential blockbuster assets, icotrokinra and rusfertide, both of which have New Drug Applications submitted between July and December 2025 for plaque psoriasis and polycythemia vera, respectively.
Strategic Profile
Pro stress-test →The company possesses a proprietary technology platform focused on discovering and developing peptide-based new chemical entities that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. With a robust cash position of $678.8 million, the company has a runway through 2028, positioning it to advance its pipeline toward commercialization.
Competitive Landscape
Pro stress-test →Protagonist operates in the competitive biopharmaceutical space targeting immunological, inflammatory, and hematological conditions. Key competitive areas include other IL-23 antagonists for psoriasis and ulcerative colitis, and treatments for blood disorders. The company's differentiation lies in its proprietary peptide platform enabling oral formulations of traditionally injectable biologics.
Industry Context
Protagonist Therapeutics Inc. operates in Biopharmaceutical Development.
Key facts
Headquarters: Newark, US · Revenue: $5.5M · Market cap: $5.26B